Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CASP6_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CASP6_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CASP6_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CASP6_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CASP6_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CASP6_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa054171 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa054172 | Colorectum | SER | Lipid and atherosclerosis | 55/1580 | 215/8465 | 6.83e-03 | 3.77e-02 | 2.74e-02 | 55 |
hsa054173 | Colorectum | SER | Lipid and atherosclerosis | 55/1580 | 215/8465 | 6.83e-03 | 3.77e-02 | 2.74e-02 | 55 |
hsa054174 | Colorectum | MSS | Lipid and atherosclerosis | 70/1875 | 215/8465 | 2.38e-04 | 1.81e-03 | 1.11e-03 | 70 |
hsa04210 | Colorectum | MSS | Apoptosis | 44/1875 | 136/8465 | 3.66e-03 | 1.66e-02 | 1.01e-02 | 44 |
hsa054175 | Colorectum | MSS | Lipid and atherosclerosis | 70/1875 | 215/8465 | 2.38e-04 | 1.81e-03 | 1.11e-03 | 70 |
hsa042101 | Colorectum | MSS | Apoptosis | 44/1875 | 136/8465 | 3.66e-03 | 1.66e-02 | 1.01e-02 | 44 |
hsa054176 | Colorectum | FAP | Lipid and atherosclerosis | 54/1404 | 215/8465 | 8.04e-04 | 5.14e-03 | 3.13e-03 | 54 |
hsa054177 | Colorectum | FAP | Lipid and atherosclerosis | 54/1404 | 215/8465 | 8.04e-04 | 5.14e-03 | 3.13e-03 | 54 |
hsa054178 | Colorectum | CRC | Lipid and atherosclerosis | 45/1091 | 215/8465 | 5.73e-04 | 5.48e-03 | 3.72e-03 | 45 |
hsa054179 | Colorectum | CRC | Lipid and atherosclerosis | 45/1091 | 215/8465 | 5.73e-04 | 5.48e-03 | 3.72e-03 | 45 |
hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0421037 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa042102 | Liver | HCC | Apoptosis | 83/4020 | 136/8465 | 9.51e-04 | 3.58e-03 | 1.99e-03 | 83 |
hsa0541742 | Liver | HCC | Lipid and atherosclerosis | 118/4020 | 215/8465 | 1.66e-02 | 3.92e-02 | 2.18e-02 | 118 |
hsa042103 | Liver | HCC | Apoptosis | 83/4020 | 136/8465 | 9.51e-04 | 3.58e-03 | 1.99e-03 | 83 |
hsa0541752 | Liver | HCC | Lipid and atherosclerosis | 118/4020 | 215/8465 | 1.66e-02 | 3.92e-02 | 2.18e-02 | 118 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CASP6 | SNV | Missense_Mutation | | c.826N>T | p.Pro276Ser | p.P276S | P55212 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1AZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CASP6 | SNV | Missense_Mutation | novel | c.596N>T | p.Thr199Met | p.T199M | P55212 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-E9-A6HE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
CASP6 | SNV | Missense_Mutation | | c.316N>A | p.Val106Ile | p.V106I | P55212 | protein_coding | tolerated(0.08) | benign(0.006) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
CASP6 | SNV | Missense_Mutation | | c.296N>C | p.Lys99Thr | p.K99T | P55212 | protein_coding | tolerated(0.41) | benign(0.111) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CASP6 | SNV | Missense_Mutation | | c.292N>T | p.Leu98Phe | p.L98F | P55212 | protein_coding | deleterious(0.05) | benign(0.209) | TCGA-A5-A0GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CASP6 | SNV | Missense_Mutation | rs752173591 | c.658N>T | p.Arg220Trp | p.R220W | P55212 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CASP6 | SNV | Missense_Mutation | novel | c.166N>C | p.Phe56Leu | p.F56L | P55212 | protein_coding | tolerated(0.63) | benign(0.005) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CASP6 | SNV | Missense_Mutation | novel | c.583G>A | p.Ala195Thr | p.A195T | P55212 | protein_coding | tolerated(0.12) | benign(0.41) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CASP6 | SNV | Missense_Mutation | novel | c.875N>A | p.Ser292Tyr | p.S292Y | P55212 | protein_coding | deleterious_low_confidence(0) | benign(0.259) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CASP6 | SNV | Missense_Mutation | | c.775C>T | p.Arg259Cys | p.R259C | P55212 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | | GAMOLENIC ACID | GAMOLENIC ACID | |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | | ALOSETRON HYDROCHLORIDE | ALOSETRON HYDROCHLORIDE | |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | | NSC-348401 | CHEMBL515505 | |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | | PURPUROGALLIN | PURPUROGALLIN | |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | | (-)-DICENTRINE | CHEMBL478754 | |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | CHEMBL197672 | EMRICASAN | |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | | NSC-228155 | CHEMBL505670 | |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | | N-(4-CARBOXYMETHENE)PHENYLPYRROLE | CHEMBL258756 | |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | | NSC-628113 | CHEMBL176599 | |
839 | CASP6 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252166767 | | |